Wednesday, March 11
Shares of Cipla were trading around Rs 1,327.80, down 0.43% in early trade on Wednesday after concerns emerged over supply disruptions in one of the company’s key products in the United States.
The weakness comes after brokerage Morgan Stanley maintained an “Underweight” rating on Cipla with a target price of Rs 1,211, citing risks to earnings following a recall of Lanreotide Injection, one of the company’s important U.S. products.
Lanreotide recall triggers concerns
Cipla’s U.S. subsidiary recently initiated a recall of unexpired batches of Lanreotide Injection, which may lead to a temporary shortage in the market.
The recall follows regulatory issues at Pharmathen International’s Rodopi facility in Greece, which is the exclusive manufacturing partner supplying Lanreotide to Cipla’s U.S. business.
The US Food and Drug Administration (USFDA) classified the plant inspection as Official Action Indicated (OAI) after identifying several compliance issues, including concerns around contamination control and aseptic processes.
As a result, production at the facility has been halted, disrupting supplies of the product.
Why the product is important for Cipla
Lanreotide is a key product for Cipla in the U.S. market and ranks among the company’s top revenue contributors there.
Because the drug is supplied through a single manufacturing partner, the regulatory action has created near-term supply risk and could delay resupply until regulatory issues are resolved.
Analysts believe prolonged disruption could lead to market share losses and pressure on earnings in FY27 and FY28.
What the brokerage says
Morgan Stanley’s view reflects the potential financial impact of the disruption:
- Rating: Underweight
- Target price: Rs 1,211
- Key concern: Delay in Lanreotide resupply to the U.S. market
- Risk: Possible loss of market share and downside to medium-term earnings forecasts
What it means for investors
While the recall may create short-term uncertainty for Cipla’s U.S. business, the company has said it is working with partners and exploring alternative manufacturing arrangements to restore supply.
The situation remains dependent on regulatory clearance and remediation efforts at the supplier facility, which will determine when production can restart.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.